The combination of high-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative therapy for patients with relapsed chemosensitive non-Hodgkin's lymphoma (NHL) and is increasingly being considered as a first-line treatment for NHL patients with poor prognosis or poor outcomes from chemotherapy. However, there is a degree of relapse following the latter which is associated with high levels of tumour cell contamination of the stem cells and/or the presence of residual malignant cells in the host following chemotherapy. Reducing the rate of relapse can be achieved by pre-transplant purging of the stem cell graft followed by post-transplant maintenance to minimise residual disease. Various methods of in vitro purging have been shown to reduce, but not eliminate, the level of stem cell contamination and invariably result in a reduced harvest. To date, this has been reflected in disappointing outcomes for the patient. In contrast, in vivo purging with rituximab during the process of stem cell mobilisation and collection does not adversely affect the yield or function of stem cells and shows a significant improvement in the level of tumour cell contamination as measured by bcl-2 clearance. The relapse potential from residual malignant cells in the host can be addressed by a programme of post-transplant rituximab maintenance therapy. In one study 17 patients with follicular lymphoma who underwent ASCT with in vivo rituximab-purged stem cells, followed by rituximab maintenance, have all remained in complete response at a median follow-up of 12.4 months. The optimum in vivo rituximab purging protocol and the precise effect in terms of overall and disease-free survival are currently being evaluated but appear to present an attractive first-line alternative for NHL patients with poor prognosis or poor outcomes following chemotherapy.
chemotherapy. In aggressive NHL, ASCT results in longer event-free and overall survival in chemosensitive relapsing patients 1 and there is increasing evidence that ASCT may also prolong survival in at least some patients with indolent disease. 2, 3 In view of these findings, ASCT is now also under consideration as first-line treatment for patients with NHL who have a poor prognosis with existing treatments, such as those with poor prognosis aggressive NHL and mantle cell lymphoma.
As ASCT is becoming a more frequently used treatment for patients with NHL, attention has focused on strategies to improve the success rate for this procedure by reducing the incidence of post-transplant relapse. Relapse is caused by persistence of residual tumour cells, either in the stem cells that are reinfused, or remaining in the host after highdose chemotherapy. In diffuse large cell lymphoma (DLCL), the most common form of aggressive NHL, Jacquy et al 4 prospectively examined stem cell harvests in patients transplanted while in complete remission. Using the highly sensitive polymerase chain reaction (PCR) technique, a high level of tumour cell contamination was detected in five of eight patients. Four of these patients relapsed early (within 4 months) while the fifth relapsed after 16 months: the three patients who had low tumour cell contamination remained disease-free for at least 30 months (Table 1 ).
In the study by Jacquy et al, 4 PCR detection of malignant cells was accomplished by the synthesis of oligonucleotide primers to detect specific gene rearrangements for each patient, a technique that would not be practicable for a large-scale study. In follicular lymphoma, 70% of patients have a characteristic t(14,18) translocation with bcl-2 gene rearrangement in the bone marrow, even where there is no histological evidence of bone marrow involvement. 5 Detection of bcl-2 rearrangement in the bone marrow after transplantation is associated with increased risk of relapse. 6, 7 III  2  High  2  I  1  Low  47+  III  3  Low  37+  IV  3  Low  30+  IV  3  High  3  IV  2  High  4  I  1  High  16  II  2  High  2 IPI = International Prognostic Index; DFS = disease-free survival.
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Detection of bcl-2 status is thus a highly sensitive and convenient method of monitoring minimal residual disease and stem cell purging in follicular NHL. Several methods of reducing the rate of relapse after ASCT, both by purging stem cell harvests of malignant cells and eliminating minimal residual disease by posttransplant maintenance therapy have been studied.
In vitro purging
A number of methods have been used to treat the harvested stem cell product to deplete residual tumour cells before infusion. In vitro purging with anti-B cell monoclonal antibodies typically results in a 2-3 log depletion of tumour cells, 8, 9 while treatment of the graft with chemotherapeutic agents such as mafosfamide has resulted in a similar level of depletion. 10 Other techniques have employed positive selection of CD34
+ cells with antibodies conjugated to magnetic beads. 11 However, while all of these techniques can reduce the level of tumour cell contamination, the majority of grafts remain PCR positive. This is further reflected in the disappointing outcomes experienced with in vitro purged ASCT: studies conducted to date have not been translated in any significant increased survival in patients receiving purged compared with unpurged stem cell grafts. 10, 12, 13 In vitro purging methods are also invariably associated with substantial cell losses, and are frequently expensive to perform.
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In vivo purging
Rituximab is a human/mouse monoclonal antibody to CD20, an antigen expressed on all cells of the B cell lineage including B cell NHL (accounting for approximately 90% of cases of NHL). Rituximab has been used effectively in the treatment of relapsed indolent and aggressive NHL 15, 16 and also in untreated patients with follicular lymphoma and a low tumour burden. 17 When combined with chemotherapy in phase II trials, rituximab has achieved response rates of 95-100% in both aggressive and indolent NHL 18, 19 and 75% in randomised phase III studies in aggressive NHL. 20 Rituximab interacts with the host immune system to kill B cells by complement-mediated cytotoxicity and antibodydependent cell-mediated cytotoxicity. 21 The antibody can also induce apoptosis in CD20-positive cells 22 and may synergise with chemotherapy in cell killing. 23, 24 Moreover, patients treated with rituximab are rapidly and effectively cleared of B cells in the peripheral blood for more than 3 months. 25 Consequently, rituximab has been used in ASCT to purge malignant cells in vivo before and during the processes of stem cell mobilisation and collection. In vivo purging is designed to prevent lymphoma cell contamination of the peripheral blood and thereby of the stem cell grafts, in contrast to in vitro purging methods which attempt to remove tumour cells from contaminated grafts after collection.
Several groups have now used in vivo purging with rituximab in patients with NHL. The optimal timing of administration of rituximab in relation to chemotherapy is not yet 
Effect of in vivo purging on stem cell number
Buckstein et al 26 directly compared stem cell yield in patients given a single purging dose of rituximab prior to stem cell mobilisation with the yield in unpurged controls. Purged patients in fact yielded a high number of CD34 + cells both in peripheral blood after mobilisation and in the harvested cells. Other studies have similarly yielded CD34 + stem cell numbers comparable to those regularly obtained from unpurged patients (Table 2) . It is clear, therefore, that in vivo purging with rituximab does not adversely affect the number of stem cells harvested.
Effect of in vivo purging on stem cell function
In addition to maintaining the numbers of CD34 + stem cells harvested from purged patients, it is essential that in vivo purging with rituximab does not adversely affect the function of the stem cells when they are reinfused. The various in vivo purging protocols used to date have indicated that this the case. Buckstein et al 26 demonstrated comparable neutrophil and platelet recovery following transplantation in purged compared with unpurged patients, and other groups have shown similar results ( Table 3) .
Clearance of bcl-2 positive cells by in vivo purging
Clearance of bcl-2-positive cells from the stem cell harvest in patients transplanted for follicular lymphoma is clearly associated with improved disease-free survival. 7 Investigators have therefore looked at this surrogate endpoint as In vivo purging and relapse prevention following ASCT C Gisselbrecht S7 Figure 1 Trial design of EBMT study of rituximab purging and maintenance in ASCT for follicular lymphoma (second remission, complete or very good partial). an indicator of potential efficacy in purging strategies. In contrast to most results obtained with in vitro purging protocols, around 80% of stem cell harvests after in vivo purging with rituximab have been bcl-2 negative (Table 4 ). In mantle cell lymphoma (MCL), rearrangements in bcl-1 rather than bcl-2 can be used to detect residual malignant cells. The study by Magni et al 30 (Table 4 ) included 10 patients with MCL, nine (90%) of whom yielded lymphoma-free stem cell harvests following in vivo purging with rituximab. In the light of these promising results, the effect of in vivo purging on disease-free and overall survival in patients receiving ASCT for NHL is now being evaluated in prospective, randomised trials.
Post-transplant administration of rituximab
While in vivo purging with rituximab is used to prevent contamination of the stem cell graft with lymphoma cells, the other potential source of relapse, namely the persistence Table 4 Lymphoma-free cell harvests following in vivo purging with rituximab (detected by PCR) + -enriched in vitro purged stem cells. Further infusions (four cycles each) were given at 6 and 12 months. As expected, these patients had a rapid depletion of B cells. This depletion was not associated with any increase in infection or significant adverse events, indicating that rituximab is well-tolerated and safe to use in this patient group recovering from a transplant. Buckstein et al 33 administered rituximab maintenance therapy to 17 patients with follicular lymphoma who had undergone ASCT with stem cells purged in vivo with a single injection of rituximab just prior to mobilisation. In this study, all assessable patients remained in complete response (including unconfirmed complete response) at a median 12.4 months follow-up. All seven patients evaluable for molecular response remained bcl-2 negative at 6 months. In the same study, 12 patients did not receive rituximab but were given ␣-interferon (␣-IFN) as post-transplant immunotherapy. In the ␣-IFN group, median followup was longer (28 months) and four patients relapsed. Eight of nine patients achieved bcl-2 clearance, although three subsequently reconverted to the bcl-2-positive state. These findings suggest the possibility of combining rituximab and ␣-IFN in post-transplant maintenance therapy to consolidate remissions in patients given ASCT for follicular lymphoma.
Ongoing studies evaluating rituximab maintenance therapy post transplant include a trial in 40 patients with minimal residual disease (lymph nodes Ͼ1 cm and Ͻ3 cm, or complete clinical remission with bcl-2 positivity) following ASCT for follicular NHL. The Groupe d'Etudes des Lymphomes de l'Adulte (GELA) is conducting a randomised study of rituximab maintenance therapy vs no treatment post ASCT in 206 patients with DLCL. The most comprehensive study is being undertaken by the European Group for Blood and Marrow Transplantation (EBMT), who are evaluating both in vivo purging and maintenance with rituximab, in a multicentre study with an enrollment goal of 460 patients with follicular lymphoma in second or third remission randomised to receive in vivo purging or no purging prior to stem cell collection and ASCT. A second ran-domisation step post transplant then assigns patients to rituximab maintenance or to observation (Figure 1 ). This study is still recruiting, and the results will help to determine the optimal uses for rituximab in the ASCT setting.
Conclusions
Rituximab, particularly in combination with chemotherapy, has proved to be an effective treatment for both indolent and aggressive NHL. One of the most striking aspects of rituximab with chemotherapy is that, in addition to increasing response rates to 75-95%, many patients convert to bcl-2 negativity. This suggests that immunochemotherapy with rituximab is effective in eliminating minimal residual disease. This provides the rationale for the use of rituximab to prevent relapse following ASCT.
Both in vivo purging and post-transplant maintenance with rituximab appear to be feasible and safe, with no adverse effects on stem cell harvesting, haematological recovery, or incidence of infections in studies to date. Initial molecular responses suggest that these strategies are effective in removing residual malignant cells from the stem cell harvest or the patient. The prospective randomised trials currently underway will help determine how best in vivo purging and/or maintenance therapy with rituximab may contribute to improved clinical outcomes for ASCT. ASCT in follicular NHL is currently used primarily for patients who have relapsed one or more times following chemotherapy, rather than as a first-choice treatment. However, if in vivo purging and maintenance can help to reduce the incidence of relapse, ASCT is likely to become an increasingly attractive option as first-line treatment for patients with poor prognostic factors, who currently have poor outcomes following chemotherapy.
